Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

NCT04796324 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
13
Enrollment
INDUSTRY
Sponsor class

Stopped Company Decision

Conditions

Interventions

Sponsor

Allarity Therapeutics